IP Group PLC Enterprise Therapeutics raises £29m
April 12 2018 - 4:19AM
RNS Non-Regulatory
TIDMIPO
IP Group PLC
12 April 2018
FOR RELEASE ON 12 April 2018
IP Group plc - Portfolio company Enterprise Therapeutics raises
GBP29m funding
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the
developer of intellectual property-based businesses, is pleased to
note that its portfolio company Enterprise Therapeutics Limited
("Enterprise" or "the Company"), has announced a GBP29 million
fundraising.
Enterprise Therapeutics, which entered the IP Group portfolio
following the combination with Touchstone Innovations, is
developing muco-regulatory therapies to treat patients with
respiratory diseases of high unmet medical need, where mucus
obstruction reduces lung function, leading to difficulty in
breathing and recurrent lung infections.
The financing, which was oversubscribed, was co-led by Versant
Ventures and Novartis Venture Fund with funding from new investor
Forbion and existing shareholders Epidarex Capital and IP
Group.
IP Group has committed to invest a total of GBP4.7 million of
the round, which is tranched and subject to the achievement of
certain milestones. The Group has invested GBP2.5 million in the
first tranche of the fundraising.
The investment will fund Enterprise Therapeutics' drug discovery
pipeline of muco-regulatory therapies into clinical development,
enabling new treatment options for cystic fibrosis, chronic
obstructive pulmonary disease and severe asthma.
For more information, please contact:
IP Group plc www.ipgroupplc.com
Alan Aubrey, Chief Executive
Officer +44 (0) 20 7444 0050
Greg Smith, Chief Financial
Officer +44 (0) 20 7444 0062/+44
Liz Vaughan-Adams, Communications (0) 7979 853802
Charlotte Street Partners
Andrew Wilson +44 (0) 7810 636995
Martha Walsh +44 (0) 7876 245962
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialisation
company which focuses on evolving great ideas, mainly from its
partner universities, into world-changing businesses. The Group has
pioneered a unique approach to developing these ideas and the
resulting businesses by providing access to business building
expertise, capital (through its 100%-owned FCA-authorised
subsidiaries IP Capital and Parkwalk Advisors), networks,
recruitment and business support. IP Group has a strong track
record of success and its portfolio comprises holdings in
early-stage to mature businesses across life sciences and
technology. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.
Group holdings in portfolio companies reflect the undiluted
beneficial equity interest excluding debt, unless otherwise
explicitly stated.
For more information, please visit our website at
www.ipgroupplc.com.
ENDS
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMGMDRZVGRZG
(END) Dow Jones Newswires
April 12, 2018 04:19 ET (08:19 GMT)
Ip (LSE:IPO)
Historical Stock Chart
From Apr 2024 to May 2024
Ip (LSE:IPO)
Historical Stock Chart
From May 2023 to May 2024